KDR: A Protein Regulating TGF-β and Angiogenesis (G3791)

Target Name: KDR

NCBI ID: G3791

Content of Review Report on KDR Target / Biomarker

KDR

KDR: A Protein Regulating TGF-β and Angiogenesis

KDR (KDR/PLCG) is a protein that is expressed in various tissues of the human body, including the placenta, bone marrow, and skin. It is a member of the growth factor receptor (GFR) family, which includes proteins that are involved in the signaling of growth factors and cytokines.

KDR has been shown to play a role in the regulation of cell proliferation and differentiation. It is a negative regulator of the TGF-β pathway, which is a well-known pathway that is involved in the regulation of cellular growth, differentiation, and survival . TGF-β is a cytokine that is involved in the development and maintenance of tissues and organs, and it is often considered to be a pro-inflammatory pathway.

KDR has been shown to regulate the activity of several transcription factors, including NF-kappa-B, AP-1, and STAT3. NF-kappa-B is a transcription factor that is involved in the regulation of inflammation and immune responses, and it is a target of many drugs that are used to treat cancer. AP-1 is a transcription factor that is involved in the regulation of cell growth and differentiation, and it is a target of several drugs that are used to treat skin cancer. STAT3 is a transcription factor that is involved in the regulation of immune responses and cell survival, and it is a target of several drugs that are used to treat autoimmune diseases.

KDR has also been shown to play a role in the regulation of cellular angiogenesis, which is the process by which new blood vessels are formed in the body. Angiogenesis is a critical process for the development and maintenance of tissues and organs, and it is often considered to be a target of many drugs that are used to treat cardiovascular disease.

In addition to its role in the regulation of angiogenesis, KDR has also been shown to play a role in the regulation of cellular signaling pathways that are involved in the development and maintenance of tissues and organs. For example, KDR has been shown to regulate the activity of the Wnt pathway, which is involved in the regulation of cell growth and differentiation.

KDR is also a potential drug target for several diseases, including cancer, cardiovascular disease, and autoimmune diseases. For example, several drugs that are used to treat cancer, including inhibitors of the TGF-β pathway, have been shown to target KDR. Similarly , several drugs that are used to treat cardiovascular disease, including statins, have been shown to target KDR. Finally, several drugs that are used to treat autoimmune diseases, including immunomodulators, have been shown to target KDR.

In conclusion, KDR is a protein that is involved in the regulation of several cellular processes that are important for the development and maintenance of tissues and organs. It is a negative regulator of the TGF-β pathway and has been shown to regulate the activity of several transcription factors, including NF-kappa-B, AP-1, and STAT3. KDR is also involved in the regulation of cellular angiogenesis and has been shown to play a role in the development and maintenance of tissues and organs. In addition to its role in cellular signaling pathways, KDR is also a potential drug target for several diseases, including cancer, cardiovascular disease, and autoimmune diseases. Further research is needed to fully understand the role of KDR in the regulation of cellular processes and to develop effective treatments for these diseases .

Protein Name: Kinase Insert Domain Receptor

Functions: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC

The "KDR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KDR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets